Dr. Greten is an expert in GI Oncology and tumor immunology. His specific research focus is liver cancer and immunology. He is trying to better understand how tumors in the liver interact with the immune system. Dr. Greten has his received his training in Medical Oncology, Gastroenterology and Hepatology in Germany and has been performing basic and translational research studies in tumor immunology for more than 20 years. He is currently studying novel immune based approaches to treat patients with primary hepatobiliary tumors and patients with tumors of the GI tract metastasizing into the liver.
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal CancerOpen - Not yet Recruiting Protocol Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-17-C-0092Referral Contacts
Contact Name Phone Number Donna Mabry Hrones 301-451-4864
A Phase 2 Study of Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination with Capecitabine and Oxaliplatin (CAPOX) in Subjects with Advanced Biliary Tract Carcinoma (BTC)Referral Contacts
Contact Name Phone Number Suzanne Fioravanti 240-760-6113
An Open Label Phase 1B/2 Trial of TRC 105 and Sorafenib in Patients with Hepatocelluar Carcinoma (HCC)Referral Contacts
Contact Name Phone Number Suzanne Fioravanti 301-594-6544
Contact Name Phone Number Suzanne Fioravanti 301.594.6544
Dr. Greten combines his medical expertise in gastroenterology, hepatology and medical oncology with his research expertise in tumor immunology. His research can be best described by the three terms “liver”, “cancer “ and “immunology”. Dr. Greten and his team try to better understand how tumors in the liver interact with the immune system and he utilized this knowledge to develop better treatment options for patients with tumors of the GI tract. Dr. Greten is an expert on immune suppressor mechanisms occurring in patients with liver cancer (and murine models of liver cancer) such as regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSC). In 2016 he published a landmark study on the role of fatty liver disease and CD4 T cells in HCC in Nature. Dr. Greten is also principle investigator of a number of immunotherapy trials in patients with GI cancer.
- Nature. 531: 253-7, 2016. [ Journal Article ]
Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression..Cancer Cell. 30: 533-47, 2016. [ Journal Article ]
- Journal of Hepatology. 2016. [ Journal Article ]
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.Gastroenterology. 135: 234-43, 2008. [ Journal Article ]
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.J. Hepatol. 59: 1007-13, 2013. [ Journal Article ]
Tim F. Greten, M.D., received his medical training at Christian Albrechts University in Kiel, Germany in 1993. He did his internship in Munich followed by a 3-year postdoctoral fellowship at the Johns Hopkins University (Baltimore, Maryland), in the laboratory of Drew Pardoll and Liz Jaffee, where he initiated his work in the field of tumor immunology. In 1999 Dr. Greten returned to Hannover Medical School, where he finished his training in internal medicine (2003), medical oncology (2004) and gastroenterology (2007). He held an associate professor position in the Department of Gastroenterology, Hepatology and Endocrinology. In February 2010 Dr. Greten joined CCR's Medical Oncology Branch as head of the Gastrointestinal Malignancy Section and was promoted as a tenured Senior Investigator in 2015.
Dr. Greten has published more than 150 peer-reviewed papers on basic tumor immunology, translational research studies in hepatocellular carcinoma (HCC) as well as on clinical trials in different gastrointestinal malignancies, including HCC. Currently, Dr. Greten serves on the Center of Excellence in Immunology Steering Committee and Center for Advanced Preclinical Research oversight committee. He is a Chairperson of the CCR Scientific Protocol Review.
|David Agdashian||Postbaccalaureate Fellow|
|Austin G. Duffy, M.D.||Associate Research Physician|
|Suzanne Fioravanti R.N., B.S.N., O.C.N.||Research Nurse Specialist|
|Qiong Fu Ph.D.||Postdoctoral Fellow (CRTA)|
|Bernd Heinrich Ph.D.||Postdoctoral Fellow (Visiting)|
|Chi Ma Ph.D.||Staff Scientist|
|Donna Mabry CRNP||Nurse Practitioner|
|Milan Sandhu||Postbaccalaureate Fellow|
|Ashish Uppala||Postbaccalaureate Fellow|
|Melissa A. Walker R.N.||Research Nurse Specialist|
|Qianfei Zhang Ph.D.||Postdoctoral Fellow|
A Phase 1/2 Study of TRC105 in Combination with Sorafenib in Heptacellular Carcinoma (HCC)A.G. Duffy, C. Ma, S.V. Ulahannan, O. Rusher, S. Fioravanti,
M. Walker, S. Carey, A.M. Venkatesan, B. Turkbey, P. Choyke,
J. Trepel, L. Cao, K. Bollen, W.D. Figg, and T.F. Greten Gastrointestinal Cancers Symposium - ASCO
San Francisco, 2015